One gram of NMN has appeared in human research, but the studies did not all use the same formulation, participants, or purpose. “NMN 1,000 mg” is therefore the beginning of an evidence comparison, not its conclusion.
Two examples are particularly useful: a short MIB-626 pharmacology study in older adults and a direct precursor comparison in healthy adults. Neither establishes that every retail one-gram product improves longevity or should be used indefinitely.
One-gram NMN research is formulation- and study-specific. Short-term blood-NAD findings do not establish a universal dose or long-term health benefit.
MIB-626 was a specific formulation
The MIB-626 trial studied a microcrystalline form of beta-NMN in 32 overweight or obese adults aged 55–80. Participants received 1,000 mg once daily, 1,000 mg twice daily, or placebo for 14 days. Blood NAD rose in a dose-related manner, with similar adverse-event frequency across groups.
Those are research regimens, not instructions for a reader. The formulation and short observation period limit what can be inferred about another product or long-term use.
The 2026 comparison asked a different question
A separate randomized, open-label study compared NR, NMN, nicotinamide, and placebo. Its analysis included 65 healthy adults; the NMN and NR arms used 1,000 mg daily for 14 days and produced comparable increases in circulating NAD.
This is useful direct biomarker evidence. It does not establish equivalent long-term health outcomes or show that the tested products are interchangeable for every user. Our NMN versus NR guide examines that distinction.
Why a retail one-gram claim needs the full panel
A front label may refer to NMN alone, a combined formula, or a daily total spread across several units. Confirm the amount of NMN itself and the serving size. Do not assume that a bottle containing another NAD precursor, direct NAD, or NMNH matches an NMN trial.
The NAD 1,000 mg guide explains how an equal mass can describe a different molecule and purchase entirely.
Two weeks cannot answer a multi-year question
Short studies can observe tolerability and biological changes while missing uncommon effects or outcomes that require longer follow-up. They also enroll selected participants rather than every person who might buy a supplement.
A high-amount label should not replace assessment of medical history, other supplements, and medications. Ask a clinician or pharmacist about the actual product instead of treating a published trial regimen as a personal recommendation.
Compare the evidence before the amount
Look for the exact study formulation, participant group, duration, comparator, and endpoint. A claim about blood NAD should remain a claim about blood NAD. A claim about function or symptoms needs evidence measuring those outcomes.
For retail comparisons involving lower amounts, read NMN 250 mg and NMN 500 mg. These pages describe different evidence questions rather than a ladder readers should climb.
Sources & reading notes
Editorial source review updated September 19, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- MIB-626: microcrystalline NMN pharmacology trial Specific formulation studied for 14 days in 32 older adults with overweight or obesity. Not a general retail dosing recommendation.
- 2026 human comparison of NR, NMN, and nicotinamide Randomized open-label 14-day study; 65 participants in the analysis. Comparable NR and NMN circulating-NAD responses do not establish long-term clinical equivalence.
- FDA: questions and answers on dietary supplements Regulatory categories and limits of premarket review.
- FDA: mixing medications and dietary supplements General interaction and surgery guidance; specific risks must be matched to the actual ingredient and medication.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.